Marinus Blåbjerg Sørensen elected as new Board Member of Eevia Health
The Board of Eevia Health Plc ("Eevia" or "The Company") has elected Marinus Blåbjerg Sørensen to fill a vacancy in the Board of Directors of Eevia after Anders Eriksson resigned last week.
Anders Eriksson resigned from the Board last week due to a significant change in his career that now requires his full attention. In accordance with the Finnish Limited Liability Companies Act (Ch. 6, Sect. 14), when a vacancy occurs mid-term, the remaining members of the Board are responsible for electing a successor to serve for the remainder of the term. Yesterday, the Board elected Marinus Blåbjerg Sørensen as the new member of the Board of Directors of Eevia Health.
Marinus Blåbjerg Sørensen is a Danish entrepreneur, businessman, and a respected leader in the nutraceutical industry. Since 1992, he has been the principal owner of New Nordic Healthbrands Ab through his investment company, Fjord Capital Aps. New Nordic is a leading provider of natural health products, including dietary supplements, with a strong international presence, particularly in Europe. Headquartered in Viken, Sweden, New Nordic Healthbrands has been listed on the First North Growth Market at NASDAQ Stockholm since January 2007.
Marinus served as the CFO of New Nordic from 1992 until his retirement in 2021. During his tenure, he played a pivotal role in the Company's development and growth, particularly in its operations and expanding its health-related product offerings. From 2006 to 2023, he was the Chairman of the Board at New Nordic Healthbrands and continues to serve as a member of the Board. Before 1992, Marinus was the CEO of Danish Natural Foods A/S and an Area Manager at Farma Foods A/S. He is also the Chairman of the Board and owner of Fjord Capital A/S and Blåbjerg-Have ApS.
“I am thrilled to join Eevia. Ultimately, the key to success is driving sales revenues. Eevia has huge global growth potential, but it needs to strengthen its sales function, build a Nordic brand, with substantiated claims on Eevia's unique products. I am ready to acquire more shares and am committed to helping the Eevia team rebuild and expand its customer base," says Marinus Blåbjerg Sørensen.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Email: stein.ulve@eeviahealth.com or investor@eeviahealth.com
Telephone: +358 400 22 5967
This information is required for Eevia Health Plc to make public in accordance with the EU's Market Abuse Regulation (MAR). The Company's contact person above made it public on 27 January 2025 at 07:30 CET.
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses global health challenges with bioactive compounds sustainably extracted from renewable plant materials. It focuses on the gut and related health, including kidney and urinary health.
Eevia Health is a manufacturer of 100% organically certified plant extracts. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.
As a pioneering company, Eevia is developing biomaterials that may dramatically impact human health. Eevia Health operates a modern green-chemistry production facility in Finland with a short value chain and environmentally friendly carbon footprint. Eevia listed its shares at the Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.